Apoptotic signaling in pancreatic cancer - Therapeutic application

Current Cancer Therapy Reviews

Volumn 5, Issue 2, 2009, Pages 122-133

  Rückert, Felix ^a   Pilarsky, Christian ^a   Saeger, Hans Detlev ^a   Grützmann, Robert ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Apoptosis pathway; Pancreatic cancer; Review; Targeted therapy

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; AMONAFIDE; AZIRIDINYLBENZOQUINONE DERIVATIVE; CAPECITABINE; CISPLATIN; DOCETAXEL; EDATREXATE; EPIRUBICIN; EXATECAN; FAZARABINE; FLUOROURACIL; FOLIC ACID ANTAGONIST; GEMCITABINE; GOSSYPOL; GYRASE INHIBITOR; IRINOTECAN; MARIMASTAT; MITOGUAZONE; MITOMYCIN; OXALIPLATIN; PACLITAXEL; RALTITREXED; SANGUINARINE; TAXANE DERIVATIVE; TIPIFARNIB; TOPOTECAN; TRIMETREXATE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CALCIUM BALANCE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL SURVIVAL; CELLULAR STRESS SIGNAL; CLINICAL TRIAL; DNA SYNTHESIS INHIBITION; DOWN REGULATION; ENDOPLASMIC RETICULUM STRESS; GENE SILENCING; GENE TARGETING; HUMAN; IONIZING RADIATION; MITOCHONDRION; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR REGRESSION;

EID: 68449094332     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339409788166760     Document Type: Review

References (196)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 2: 71-96.
2. Stojadinovic A, Brooks A, Hoos A, et al. An evidence-based approach to the surgical management of resectable pancreatic adenocarcinoma. J Am Coll Surg 2003; 6: 954-64.
3. Brown JM, Wouters BG. Apoptosis: mediator or mode of cell killing by anticancer agents? Drug Resist Updat 2001; 2: 135-6.
4. Schulze-Bergkamen H, Krammer PH. Apoptosis in cancer - implications for therapy. Semin Oncol 2004; 1: 90-119.
5. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 34: 4798-811.
6. Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 1992; 2:121-39.
7. Weinstein JN, Myers TG, O'Connor PM, et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997; 5298: 343-9.
8. Mandoky L, Szende B, Geczi L, et al. Apoptosis regulation and spontaneous apoptosis index of testicular germ cell tumors are associated with differentiation and resistance to systemic treatment. Anticancer Res 2008; 3A: 1641-9.
9. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994; 4: 539-42.
10. Magistrelli P, Coppola R, Tonini G, et al. Apoptotic index or a combination of Bax/Bcl-2 expression correlate with survival after resection of pancreatic adenocarcinoma. J Cell Biochem 2006; 1: 98-108.
11. Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet 2007; 9574: 1742-57.
12. Rupnow BA, Knox SJ. The role of radiation-induced apoptosis as a determinant of tumor responses to radiation therapy. Apoptosis 1999; 2: 115-43.
13. Vermeulen K, Van Bockstaele DR, Berneman ZN. Apoptosis: mechanisms and relevance in cancer. Ann Hematol 2005; 10: 627-39.
14. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005; 3: 231-7.
15. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004; 7015: 307-15.
16. Roninson IB, Broude EV, Chang BD. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 2001; 5: 303-13.
17. Castedo M, Perfettini JL, Roumier T, et al. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004; 16: 2825-37.
18. Kroemer G, El-Deiry WS, Golstein P, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. Cell Death Differ 2005: 1463-7.
19. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998; 5381: 1312-6.
20. Thornberry NA. Caspases: a decade of death research. Cell Death Differ 1999; 11: 1023-7.
21. Hamacher R, Schmid RM, Saur D, Schneider G. Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer 2008; 1: 64.
22. Van Cruchten S, Van Den Broeck W. Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat Histol Embryol 2002; 4: 214-23.
23. Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene 2003; 53: 8543-67.
24. Nawrocki ST, Carew JS, Pino MS, et al. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 2005; 24: 11658-66.
25. Rao RV, Ellerby HM, Bredesen DE. Coupling endoplasmic reticulum stress to the cell death program. Cell Death Differ 2004; 4: 372-80.
26. Westphal S, Kalthoff H. Apoptosis: targets in pancreatic cancer. Mol Cancer 2003: 6.
27. Glazyrin AL, Adsay VN, Vaitkevicius VK, Sarkar FH. CD95-related apoptotic machinery is functional in pancreatic cancer cells. Pancreas 2001; 4: 357-65.
28. Satoh K, Kaneko K, Hirota M, et al. Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. Pancreas 2001; 3: 251-8.
29. Vogler M, Durr K, Jovanovic M, Debatin KM, Fulda S. Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene 2007; 26: 248-257.
30. Hinz S, Trauzold A, Boenicke L, et al. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene 2000; 48: 5477-86.
31. Gerhard MC, Schmid RM, Hacker G. Analysis of the cytochrome c-dependent apoptosis apparatus in cells from human pancreatic carcinoma. Br J Cancer 2002; 6: 893-8.
32. Walczak H, Krammer PH. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res 2000; 1: 58-66.
33. Strasser A, O'Connor L, Dixit VM. Apoptosis signaling. Annu Rev Biochem 2000: 217-45.
34. Baker SJ, Reddy EP. Transducers of life and death: TNF receptor superfamily and associated proteins. Oncogene 1996; 1: 1-9.
35. Werner AB, de Vries E, Tait SW, Bontjer I, Borst J. TRAIL receptor and CD95 signal to mitochondria via FADD, caspase-8/10, Bid, and Bax but differentially regulate events downstream from truncated Bid. J Biol Chem 2002; 43: 40760-7.
36. Morgan M, Thorburn J, Pandolfi PP, Thorburn A. Nuclear and cytoplasmic shuttling of TRADD induces apoptosis via different mechanisms. J Cell Biol 2002; 6: 975-84.
37. Kischkel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 1995; 22: 5579-88.
38. Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998; 6: 1675-87.
39. Trauzold A, Wermann H, Arlt A, et al. CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene 2001; 31: 4258-69.
40. Krammer PH. CD95's deadly mission in the immune system. Nature 2000; 6805: 789-95.
41. Bernstorff WV, Glickman JN, Odze RD, et al. Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape. Cancer 2002; 10: 2552-60.
42. Elnemr A, Ohta T, Yachie A, et al. Human pancreatic cancer cells disable function of Fas receptors at several levels in Fas signal transduction pathway. Int J Oncol 2001; 2: 311-6.
43. Ohta T, Elnemr A, Kitagawa H, et al. Fas ligand expression in human pancreatic cancer. Oncol Rep 2004; 4: 749-54.
44. Tsuji S, Hosotani R, Yonehara S, et al. Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma. Int J Cancer 2003; 1: 17-25.
45. Ungefroren H, Voss M, Bernstorff WV, et al. Immunological escape mechanisms in pancreatic carcinoma. Ann N Y Acad Sci 1999: 243-51.
46. Strand S, Galle PR. Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications. Mol Med Today 1998; 2: 63-8.
47. Elnemr A, Ohta T, Yachie A, et al. Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape. Int J Oncol 2001; 1: 33-9.
48. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003; 2: 181-90.
49. Bai J, Sui J, Demirjian A, et al. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res 2005; 6: 2344-52.
50. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003; 1: 66-75.
51. Wang P, Zhang J, Bellail A, et al. Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells. Cell Signal 2007; 11: 2237-46.
52. Ringel B, Ibrahim SM, Kohler H, et al. Apoptotic molecules in pancreatic carcinoma cell lines. Ann N Y Acad Sci 1999: 175-8.
53. Ozawa F, Friess H, Kleeff J, et al. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett 2001; 1: 71-81.
54. DeRosier LC, Buchsbaum DJ, Oliver PG, et al. Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer. Clin Cancer Res 2007; 18 Pt 2: 5535s-43s.
55. Mori T, Doi R, Toyoda E, et al. Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer. Surgery 2005; 1: 71-7.
56. Liao Q, Friess H, Kleeff J, Buchler MW. Differential expression of TRAIL-R3 and TRAIL-R4 in human pancreatic cancer. Anticancer Res 2001; 5: 3153-9.
57. Krueger A, Baumann S, Krammer PH, Kirchhoff S. FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 2001; 24: 8247-54.
58. Trauzold A, Schmiedel S, Sipos B, et al. PKCmu prevents CD95-mediated apoptosis and enhances proliferation in pancreatic tumour cells. Oncogene 2003; 55: 8939-47.
59. Ungefroren H, Kruse ML, Trauzold A, et al. FAP-1 in pancreatic cancer cells: functional and mechanistic studies on its inhibitory role in CD95-mediated apoptosis. J Cell Sci 2001; Pt 15: 2735-46.
60. Grutzmann R, Pilarsky C, Ammerpohl O, et al. Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. Neoplasia 2004; 5: 611-22.
61. Trauzold A, Schmiedel S, Oestern S, et al. Concerted deregulations of multiple apoptosis-controlling genes in pancreatic carcinoma cells. Ann N Y Acad Sci 2003: 510-3.
62. Pilarsky C, Ammerpohl O, Sipos B, et al. Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling. J Cell Mol Med 2008.
63. Adams JM, Cory S. Apoptosomes: engines for caspase activation. Curr Opin Cell Biol 2002; 6: 715-20.
64. Decaudin D, Marzo I, Brenner C, Kroemer G. Mitochondria in chemotherapy-induced apoptosis: a prospective novel target of cancer therapy (review). Int J Oncol 1998; 1: 141-52.
65. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 9: 647-56.
66. Cande C, Cecconi F, Dessen P, Kroemer G. Apoptosis-inducing factor (AIF): key to the conserved caspase-independent pathways of cell death? J Cell Sci 2002; Pt 24: 4727-34.
67. Ekert PG, Vaux DL. The mitochondrial death squad: hardened killers or innocent bystanders? Curr Opin Cell Biol 2005; 6: 626-30.
68. Fuster JJ, Sanz-Gonzalez SM, Moll UM, Andres V. Classic and novel roles of p53: prospects for anticancer therapy. Trends Mol Med 2007; 5: 192-9.
69. Sax JK, El-Deiry WS. p53 downstream targets and chemosensitivity. Cell Death Differ 2003; 4: 413-7.
70. Chipuk JE, Kuwana T, Bouchier-Hayes L, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004; 5660: 1010-4.
71. Mihara M, Erster S, Zaika A, et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003; 3: 577-90.
72. O'Neill J, Manion M, Schwartz P, Hockenbery DM. Promises and challenges of targeting Bcl-2 anti-apoptotic proteins for cancer therapy. Biochim Biophys Acta 2004; 1: 43-51.
73. Bouillet P, Strasser A. BH3-only proteins - evolutionarily conserved proapoptotic Bcl-2 family members essential for initiating programmed cell death. J Cell Sci 2002; Pt 8: 1567-74.
74. Tinel A, Tschopp J. The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science 2004; 5672: 843-6.
75. Shi X, Liu S, Kleeff J, Friess H, Buchler MW. Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 2002; 4: 354-62.
76. Miyamoto Y, Hosotani R, Wada M, et al. Immunohistochemical analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 expression in pancreatic cancers. Oncology 1999; 1: 73-82.
77. Sharma J, Srinivasan R, Majumdar S, et al. Bcl-XL protein levels determine apoptotic index in pancreatic carcinoma. Pancreas 2005; 4: 337-42.
78. Qiao JG, Zhang YQ, Yin YC, Tan Z. Expression of Survivin in pancreatic cancer and its correlation to expression of Bcl-2. World J Gastroenterol 2004; 18: 2759-61.
79. Okamoto K, Ocker M, Neureiter D, et al. bcl-2-specific siRNAs restore gemcitabine sensitivity in human pancreatic cancer cells. J Cell Mol Med 2007; 2: 349-61.
80. Mahon PC, Baril P, Bhakta V, et al. S100A4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer. Cancer Res 2007; 14: 6786-95.
81. Okami J, Simeone DM, Logsdon CD. Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer. Cancer Res 2004; 15: 5338-46.
82. Erkan M, Kleeff J, Esposito I, et al. Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene 2005; 27: 4421-32.
83. Evans JD, Cornford PA, Dodson A, et al. Detailed tissue expression of bcl-2, bax, bak and bcl-x in the normal human pancreas and in chronic pancreatitis, ampullary and pancreatic ductal adenocarcinomas. Pancreatology 2001; 3: 254-62.
84. Cecconi F. Apaf1 and the apoptotic machinery. Cell Death Differ 1999; 11: 1087-98.
85. Shiozaki EN, Shi Y. Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology. Trends Biochem Sci 2004; 9: 486-94.
86. Phillips PA, Dudeja V, McCarroll JA, et al. Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res 2007; 19: 9407-16.
87. Srinivasula SM, Gupta S, Datta P, et al. Inhibitor of apoptosis proteins are substrates for the mitochondrial serine protease Omi/HtrA2. J Biol Chem 2003; 34: 31469-72.
88. Vaux DL, Silke J. HtrA2/Omi, a sheep in wolf's clothing. Cell 2003; 3: 251-3.
89. Lopes RB, Gangeswaran R, McNeish IA, Wang Y, Lemoine NR. Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy. Int J Cancer 2007.
90. Saelens X, Festjens N, Vande Walle L, et al. Toxic proteins released from mitochondria in cell death. Oncogene 2004; 16: 2861-74.
91. Li LY, Luo X, Wang X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 2001; 6842: 95-9.
92. Larisch S. The ARTS connection: role of ARTS in apoptosis and cancer. Cell Cycle 2004; 8: 1021-3.
93. Marshall KR, Gong M, Wodke L, et al. The human apoptosis-inducing protein AMID is an oxidoreductase with a modified flavin cofactor and DNA binding activity. J Biol Chem 2005; 35: 30735-40.
94. Fok JY, Mehta K. Tissue transglutaminase induces the release of apoptosis inducing factor and results in apoptotic death of pancreatic cancer cells. Apoptosis 2007; 8: 1455-63.
95. Yang L, Cao Z, Yan H, Wood WC. Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res 2003; 20: 6815-24.
96. Esposito I, Kleeff J, Abiatari I, et al. Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancer. J Clin Pathol 2007; 8: 885-95.
97. Giagkousiklidis S, Vellanki SH, Debatin KM, Fulda S. Sensitization of pancreatic carcinoma cells for gamma-irradiation-induced apoptosis by XIAP inhibition. Oncogene 2007; 49: 7006-16.
98. Shrikhande SV, Kleeff J, Kayed H, et al. Silencing of X-linked inhibitor of apoptosis (XIAP) decreases gemcitabine resistance of pancreatic cancer cells. Anticancer Res 2006; 5A: 3265-73.
99. Karikari CA, Roy I, Tryggestad E, et al. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein. Mol Cancer Ther 2007.
100. Satoh K, Kaneko K, Hirota M, et al. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 2001; 2: 271-8.
101. Zhou M. Transcriptional Regulation of Survivin: New Target for Cancer Treatment. Curr Cancer Ther Rev 2006; 4: 331-9.
102. Lohr JM. Medical treatment of pancreatic cancer. Expert Rev Anticancer Ther 2007; 4: 533-44.
103. Pierantoni C, Pagliacci A, Scartozzi M, et al. Pancreatic cancer: progress in cancer therapy. Crit Rev Oncol Hematol 2008; 1: 27-38.
104. Esposito I, Kleeff J, Bergmann F, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 2008; 6: 1651-60.
105. Nakao A, Fujii T, Sugimoto H, et al. Oncological problems in pancreatic cancer surgery. World J Gastroenterol 2006; 28: 4466-72.
106. Ducreux M, Boige V, Malka D. Emerging drugs in pancreatic cancer. Expert Opin Emerg Drugs 2004; 1: 73-89.
107. Kim R, Emi M, Tanabe K, Uchida Y, Arihiro K. The role of apoptotic or nonapoptotic cell death in determining cellular response to anticancer treatment. Eur J Surg Oncol 2006; 3: 269-77.
108. Kastl S, Brunner T, Herrmann O, et al. Neoadjuvant radio-chemotherapy in advanced primarilynon-resectable carcinomas of the pancreas. Eur J Surg Oncol 2000; 6: 578-82.
109. Willett CG, Safran H, Abrams RA, Regine WF, Rich TA. Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials. Int J Radiat Oncol Biol Phys 2003; 4 Suppl:31-7.
110. Neoptolemos JP. Clinical evidence does not support the use of adjuvant radiotherapy in pancreatic cancer. Nat Clin Pract Oncol 2008; 8: 431.
111. Wolff RA, Chiao P, Lenzi R, et al. Current approaches and future strategies for pancreatic carcinoma. Invest New Drugs 2000; 1: 43-56.
112. Burris HA, 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 6: 2403-13.
113. Hubbard KP, Pazdur R, Ajani JA, et al. Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer. Am J Clin Oncol 1992; 6: 524-7.
114. Carlson RW, Doroshow JH, Odujinrin OO, et al. Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas. A phase II study of the Northern California Oncology Group. Invest New Drugs 1990; 4: 387-9.
115. Casper ES, Schwartz GK, Johnson B, Kelsen DP. Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma. Invest New Drugs 1992; 4: 313-6.
116. Casper ES, Schwartz GK, Kelsen DP. Phase II trial of fazarabine (arabinofuranosyl-5-azacytidine) in patients with advanced pancreatic adenocarcinoma. Invest New Drugs 1992; 3: 205-9.
117. Bukowski RM, Fleming TR, Macdonald JS, et al. Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. A Southwest Oncology Group study. Cancer 1993; 2: 322-5.
118. Linke K, Pazdur R, Abbruzzese JL, et al. Phase II study of amonafide in advanced pancreatic adenocarcinoma. Invest New Drugs 1991; 4: 353-6.
119. Rougier P, Adenis A, Ducreux M, et al. A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer 2000; 8: 1016-25.
120. Okada S, Sakata Y, Matsuno S, et al. Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan. Br J Cancer 1999; 3-4: 438-43.
121. Sugarman SM PR, Daugherty K, Evans D, Winn R, Dubovsky D, Goodwin JW, Abbruzzese JL. A phase II trial of topotecan for the treatment of unresectable pancreatic cancer. Proc Am Soc Clin Oncol 1994; 224a: (abstract #684).
122. Wagener DJ, Verdonk HE, Dirix LY, et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 1995; 2: 129-32.
123. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 1: 29-34.
124. Rubin J, Gallagher JG, Schroeder G, et al. Phase II trials of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma. Cancer 1996; 9: 1888-91.
125. Ducreux M, Rougier P, Pignon JP, et al. A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 2002; 8: 1185-91.
126. Pazdur R, Meropol NJ, Casper ES, et al. Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer. Invest New Drugs 1996; 4: 355-8.
127. Kang SP, Saif MW. Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy. JOP 2008; 3: 251-66.
128. Cihak A, Vesely J, Skoda J. Azapyrimidine nucleosides: metabolism and inhibitory mechanisms. Adv Enzyme Regul 1985: 335-54.
129. Bijnsdorp IV, Comijn EM, Padron JM, Gmeiner WH, Peters GJ. Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition. Oncol Rep 2007; 1: 287-91.
130. Parker WB, Cheng YC. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 1990; 3: 381-95.
131. Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 1990; 14: 4417-22.
132. Shinchi H, Maemura K, Noma H, et al. Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer. Br J Cancer 2007; 9: 1353-7.
133. Schweitzer BI, Dicker AP, Bertino JR. Dihydrofolate reductase as a therapeutic target. FASEB J 1990; 8: 2441-52.
134. Purcell WT, Ettinger DS. Novel antifolate drugs. Curr Oncol Rep 2003; 2: 114-25.
135. Perez JM, Camazon M, Alvarez-Valdes A, et al. Synthesis, characterization and DNA modification induced by a novel Pt(IV)-bis (monoglutarate) complex which induces apoptosis in glioma cells. Chem Biol Interact 1999; 2: 99-115.
136. Peng YC, Kuo HS, Tsai HD, Yang YP, Lin YL. The lethal effect of bis-type azridinylnaphthoquinone derivative on oral cancer cells (OEC-M1) associated with anti-apoptotic protein bcl-2. Bioorg Med Chem 2006; 1: 263-72.
137. Marques MP, Gil FP, Calheiros R, et al. Biological activity of antitumoural MGBG: the structural variable. Amino Acids 2008; 4: 555-64.
138. Norton JT, Witschi MA, Luong L, et al. Synthesis and anticancer activities of 6-amino amonafide derivatives. Anticancer Drugs 2008; 1: 23-36.
139. Rothenberg ML. Topoisomerase I inhibitors: review and update. Ann Oncol 1997; 9: 837-55.
140. Veitia R, David S, Barbier P, et al. Proteolysis of microtubule associated protein 2 and sensitivity of pancreatic tumours to docetaxel. Br J Cancer 2000; 4: 544-9.
141. Ganansia-Leymarie V, Bischoff P, Bergerat JP, Holl V. Signal transduction pathways of taxanes-induced apoptosis. Curr Med Chem Anticancer Agents 2003; 4: 291-306.
142. Janssen K, Pohlmann S, Janicke RU, Schulze-Osthoff K, Fischer U. Apaf-1 and caspase-9 deficiency prevents apoptosis in a Baxcontrolled pathway and promotes clonogenic survival during paclitaxel treatment. Blood 2007; 10: 3662-72.
143. Fabbri F, Amadori D, Carloni S, et al. Mitotic catastrophe and apoptosis induced by docetaxel in hormone-refractory prostate cancer cells. J Cell Physiol 2008.
144. Hidalgo M, Castellano D, Paz-Ares L, et al. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 1999; 2: 585-92.
145. Rocha Lima CM, Savarese D, Bruckner H, et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 2002; 5: 1182-91.
146. Heinemann V, Wilke H, Mergenthaler HG, et al. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 2000; 11: 1399-403.
147. Louvet C, Andre T, Lledo G, et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 2002; 6: 1512-8.
148. Aksu G, Sarper B, Ulutin C, Bakkal H. Recent Advances in Combined Modality Treatment for Locally Advanced Pancreatic Cancer. Curr Cancer Ther Rev 2005; 3: 227-37.
149. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 15: 3270-5.
150. Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomised phase III study of the Gruppo Oncologia dell'Italia Meridionale; Cancer 2002; 4: 902-10.
151. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24: 3946-52.
152. Lutz MP, Van Cutsem E, Wagener T, et al. Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the european organisation for research and treatment of cancer gastrointestinal group. J Clin Oncol 2005; 36: 9250-6.
153. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004; 18: 3776-83.
154. Abou-Alfa GK, Letourneau R, Harker G, et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 2006; 27: 4441-7.
155. Bramhall SR, Schulz J, Nemunaitis J, et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002; 2: 161-7.
156. Van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 8: 1430-8.
157. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 15: 3509-16.
158. Maisey N, Chau I, Cunningham D, et al. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 2002; 14: 3130-6.
159. Reni M, Cordio S, Milandri C, et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 2005; 6: 369-76.
160. Conroy T, Paillot B, Francois E, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer-a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol 2005; 6: 1228-36.
161. Belka C, Jendrossek V, Pruschy M, et al. Apoptosis-modulating agents in combination with radiotherapy-current status and outlook. Int J Radiat Oncol Biol Phys 2004; 2: 542-54.
162. Bakhanashvili M, Rahav G. A role for tumor suppressor protein p53 in the fidelity of DNA synthesis and resistance towards nucleoside analogs. Curr Cancer Ther Rev 2006; 3: 231-41.
163. Koliopanos A, Avgerinos C, Paraskeva C, et al. Molecular aspects of carcinogenesis in pancreatic cancer. Hepatobiliary Pancreat Dis Int 2008; 4: 345-56.
164. Plate JM. Current immunotherapeutic strategies in pancreatic cancer. Surg Oncol Clin N Am 2007; 4: 919-43, xi.
165. Engelhardt K, Riley C, Cooke L, Mahadevan D. Monoclonal antibody therapies targeting pancreatic ductal adenocarcinoma. Curr Drug Discov Technol 2006; 4: 231-43.
166. Diamantidis M, Tsapournas G, Kountouras J, Zavos C. New aspects of regulatory signaling pathways and novel therapies in pancreatic cancer. Curr Mol Med 2008; 1: 12-37.
167. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 6: 420-30.
168. Radfar S, Davrinche C, Hollande E. Serial in vivo loss and in vitro gain of Fas expression and function in human cancerous pancreatic duct cells. Int J Cancer 2005; 2: 214-23.
169. Schmiegel WH, Caesar J, Kalthoff H, et al. Antiproliferative effects exerted by recombinant human tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) on human pancreatic tumor cell lines. Pancreas 1988; 2: 180-8.
170. Raitano AB, Scuderi P, Korc M. Binding and biological effects of tumor necrosis factor and gamma interferon in human pancreatic carcinoma cells. Pancreas 1990; 3: 267-77.
171. Egberts JH, Cloosters V, Noack A, et al. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 2008; 5: 1443-50.
172. Takahashi H, Funahashi H, Sawai H, et al. Synthetic serine protease inhibitor, gabexate mesilate, prevents nuclear factor-kappaB activation and increases TNF-alpha-mediated apoptosis in human pancreatic cancer cells. Dig Dis Sci 2007; 10: 2646-52.
173. Sethi G, Aggarwal BB. Role of NF-?B and NF-?B-regulated Gene Products in Chemoresistance and Radioresistance. Curr Cancer Ther Rev 2006; 2: p115-25.
174. Koschny R, Walczak H, Ganten TM. The promise of TRAIL - potential and risks of a novel anticancer therapy. J Mol Med 2007; 9: 923-35.
175. Trauzold A, Siegmund D, Schniewind B, et al. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 2006; 56: 7434-9.
176. Strimpakos A, Saif MW, Syrigos KN. Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Rev 2008; 3: 495-522.
177. Pino SM, Xiong HQ, McConkey D, Abbruzzese JL. Novel therapies for pancreatic adenocarcinoma. Curr Oncol Rep 2004; 3: 199-206.
178. Withey J, Mark R. RNA Interference: A New Targeted Tumour Therapy? Curr Cancer Ther Rev 2005; 1: 11-7.
179. Hanna S, Chung T, Hecht J. Safety and efficacy of TNFerade in unresectable locally advanced pancreatic cancer: results of the first two cohorts of a dose escalating study. Gastrointestinal Cancer Symposium; 2004; San Fransisco, LA, USA; 2004.
180. Katz MH, Spivack DE, Takimoto S, et al. Gene therapy of pancreatic cancer with green fluorescent protein and tumor necrosis factor-related apoptosis-inducing ligand fusion gene expression driven by a human telomerase reverse transcriptase promoter. Ann Surg Oncol 2003; 7: 762-72.
181. Jacob D, Davis J, Zhu H, et al. Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter. Clin Cancer Res 2004; 10: 3535-41.
182. Masui T, Hosotani R, Ito D, et al. Bcl-XL antisense oligonucleotides coupled with antennapedia enhances radiation-induced apoptosis in pancreatic cancer. Surgery 2006; 2: 149-60.
183. Tsuji N, Asanuma K, Kobayashi D, Yagihashi A, Watanabe N. Introduction of a survivin gene-specific small inhibitory RNA inhibits growth of pancreatic cancer cells. Anticancer Res 2005; 6B: 3967-72.
184. Li Y, Jian Z, Xia K, et al. XIAP is related to the chemoresistance and inhibited its expression by RNA interference sensitize pancreatic carcinoma cells to chemotherapeutics. Pancreas 2006; 3: 288-96.
185. LaCasse EC, Cherton-Horvat GG, Hewitt KE, et al. Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res 2006; 17: 5231-41.
186. Ahsan H, Reagan-Shaw S, Breur J, Ahmad N. Sanguinarine induces apoptosis of human pancreatic carcinoma AsPC-1 and BxPC-3 cells via modulations in Bcl-2 family proteins. Cancer Lett 2007; 2: 198-208.
187. Huang S, Sinicrope FA. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res 2008; 8: 2944-51.
188. Wang G, Nikolovska-Coleska Z, Yang CY, et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem 2006; 21: 6139-42.
189. Wang Z, Song W, Aboukameel A, et al. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer. Int J Cancer 2008; 4: 958-66.
190. Mohammad RM, Wang S, Banerjee S, et al. Nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL, (-)-Gossypol, enhances biological effect of genistein against BxPC-3 human pancreatic cancer cell line. Pancreas 2005; 4: 317-24.
191. Karikari CA, Roy I, Tryggestad E, et al. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein. Mol Cancer Ther 2007; 3: 957-66.
192. Mori T, Doi R, Kida A, et al. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells. J Surg Res 2007; 2: 281-6.
193. Nawrocki ST, Carew JS, Pino MS, et al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006; 7: 3773-81.
194. Yeung BH, Huang DC, Sinicrope FA. PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells. J Biol Chem 2006; 17: 11923-32.
195. Carracedo A, Gironella M, Lorente M, et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res 2006; 13: 6748-55.
196. Kunnumakkara AB, Guha S, Krishnan S, et al. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 2007; 8: 3853-61.